MabPlex Closes ￥500M Series B Funding Round

According to lieyunwang.com, MabPlex International Ltd. ("MabPlex") has closed Series B financing of 500 million yuan, led by Detong Capital and Golden China Fund, with participation from existing investors GF Venture Capital, Huachen Caijin, Yantai Financial Holdings and Zhongyi Huiyin Investment, and new investors including Sunshine Insurance, Orbimed, China Merchants Securities, Xin Zhen Tian Ying Fund, Finnova Investment, Horus Capital, Qiaodao Fund and Ligong Investment. The existing shareholder SDIC Venture Capital also participated in the latest round through the transfer of shares.

In January 2019, MabPlex announced the completion of ￥400 million Series A financing, led by investment institutions such as SDIC Venture Capital，Shenzhen Venture Capital, and others.

Founded in June 2013, MabPlex provides global CDMO services in the development and manufacturing of biopharmaceuticals, including mAbs, recombinant proteins, ADCs, and bispecifics. It offers partners contract services from DNA to finished drug products. With technical expertise, MabPlex provides effective high-quality solutions for biomanufacturing. At both its US R&D site and manufacturing site in Yantai, China, MabPlex delivers its commitment to clients through quality manufacturing.

At present, there are 9 multi-scale cell culture lines of 200 to 2000L and large-scale ADC production lines in MabPlex. It can apply for the IND/BLA declaration in accordance with standards of FDA, EMA, NMPA, TGA, and others. In 2019, MabPlex was recognized as a national high-tech enterprise.

Detong Capital is a private equity investment firm that provides growth capital to early and expansion-stage companies. It invests in dynamic businesses that have high growth potential, strong management teams, and demonstrated revenue models in both technology-based and traditional industries.

Golden China Fund is a partnership fund initiated and established by Tasly Group in February 2012. It mainly invests in the medical and pharmaceutical fields. Its phase 1 fund has raised 710 million yuan. By October 2014, the company had invested in six projects, involving an amount of 324 million yuan.